Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Active-comparator Controlled, Parallel-group Study, to Evaluate the Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With Type 2 Diabetes Mellitus

NCT05140694 is registered in ClinicalTrials.gov with Seoul National University Bundang Hospital as lead sponsor.

NCT NCT05140694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05140694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Active-comparator Controlled, Parallel-group Study, to Evaluate the Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With Type 2 Diabetes Mellitus
Lead sponsor
Seoul National University Bundang Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
December 1, 2023
Completion date
December 31, 2025
Enrollment
135 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic-associated fatty liver disease, type 2 diabetes